Ticker LaunchIPO · IVA
Inventiva S.A.
Inventiva S.A. (IVA) priced its initial public offering on Jul 13, 2020, raising $107.7M, and listed on Nasdaq Global Market. Jefferies was lead-left underwriter, joined by Stifel, Guggenheim and H.C. Wainwright and others. Cooley advised the company and Davis Polk advised the underwriters.
Inventiva S.A. is a clinical-stage biopharmaceutical company developing oral small molecule therapies for non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses and other diseases. Its two clinical candidates are lanifibranor for NASH and odiparcil for mucopolysaccharidoses, supported by a library of proprietary molecules and its own research facility.
- Status
- IPO
- Ticker
- IVA
- Exchange
- Nasdaq Global Market
- Priced
- Jul 13, 2020
- Price range
- $13.40–$15.40
- Raised
- $107.7M
- First filed
- Jun 19, 2020
- Underwriters
- Jefferies, Stifel, Guggenheim, H.C. Wainwright, Roth Capital and KBC
- Company counsel
- Cooley
- Underwriters' counsel
- Davis Polk
- Sector
- Biotech & pharma
- Country / state
- France
More on this listing for subscribers
- Lock-up period and expiry date
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (F-1) first filed Jun 19, 2020
- Latest amendment Jul 8, 2020
- Final prospectus (424B4) Jul 13, 2020
- All filings on EDGAR CIK 1756594
Other Biotech & pharma IPOs in 2020
- ALX Oncology Holdings IncALXO · Jul 17, 2020 · $161.5M
- Pandion Therapeutics, Inc.PAND · Jul 17, 2020 · $135M
- Relay Therapeutics, Inc.RLAY · Jul 16, 2020 · $400M
- Nkarta, Inc.NKTX · Jul 13, 2020 · $252M
- Poseida Therapeutics, Inc.PSTX · Jul 10, 2020 · $224M
- Amryt Pharma plcAMYT · Jul 8, 2020